• Patients & Families
• Education
• Research
• Community

• Referring Physicians
• Find a Physician
• Departments & Centers
• About URMC

• Libraries
• Alumni
• Giving

• Overview
• Projects
• Publications
• Personnel

Principal Investigator

Andrea Sant, Ph.D. University of Rochester work Box 609 601 Elmwood Ave Rochester NY 14642 office: KMRB 3-9645 p 585-275-9798 andrea_sant@urmc.rochester.edu

Recent Publications

The following list was auto-generated 4 days ago.

• 1. Nayak JL
  2. Fitzgerald TF
  3. Richards KA
  4. Yang H
  5. Treanor JJ
  6. Sant AJ
  (2013 Jan 15). CD4+ T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A(H1N1) virus subtype H1N1 vaccine. J Infect Dis. 207, 297-305.
• 1. Richards KA
  2. Chaves FA
  3. Alam S
  4. Sant AJ
  (2012 Dec 17). Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins. Vaccine. 31, 219-25.
• 1. Nayak JL
  2. Sant AJ
  (2012 Aug 01). Loss in CD4 T-cell responses to multiple epitopes in influenza due to expression of one additional MHC class II molecule in the host. Immunology. 136, 425-36.
• 1. Sant AJ
  2. McMichael A
  (2012 Jul 30). Revealing the role of CD4(+) T cells in viral immunity. J Exp Med. 209, 1391-5.
• 1. Chaves FA
  2. Lee AH
  3. Nayak JL
  4. Richards KA
  5. Sant AJ
  (2012 May 01). The utility and limitations of current Web-available algorithms to predict peptides recognized by CD4 T cells in response to pathogen infection. J Immunol. 188, 4235-48.
• 1. Leddon SA
  2. Sant AJ
  (2012 Jan 01). The peptide specificity of the endogenous T follicular helper cell repertoire generated after protein immunization. PLoS One. 7, e46952.
• 1. Alam S
  2. Sant AJ
  (2011 Dec 01). Infection with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus. J Virol. 85, 13310-21.
• 1. Richards KA
  2. Chaves FA
  3. Sant AJ
  (2011 Jun 01). The memory phase of the CD4 T-cell response to influenza virus infection maintains its diverse antigen specificity. Immunology. 133, 246-56.
• 1. Nayak JL
  2. Sant AJ
  (2011 Mar 01). T cell immunology for the clinician. Pediatr Infect Dis J. 30, 248-50.
• 1. Richards KA
  2. Topham D
  3. Chaves FA
  4. Sant AJ
  (2010 Nov 01). Cutting edge: CD4 T cells generated from encounter with seasonal influenza viruses and vaccines have broad protein specificity and can directly recognize naturally generated epitopes derived from the live pandemic H1N1 virus. J Immunol. 185, 4998-5002.
• 1. Leddon SA
  2. Sant AJ
  (2010 Aug 01). Generation of MHC class II-peptide ligands for CD4 T-cell allorecognition of MHC class II molecules. Curr Opin Organ Transplant. 15, 505-11.
• 1. Nayak JL
  2. Richards KA
  3. Chaves FA
  4. Sant AJ
  (2010 Apr 01). Analyses of the specificity of CD4 T cells during the primary immune response to influenza virus reveals dramatic MHC-linked asymmetries in reactivity to individual viral proteins. Viral Immunol. 23, 169-80.
• 1. Weaver JM
  2. Sant AJ
  (2009 Dec 01). Understanding the focused CD4 T cell response to antigen and pathogenic organisms. Immunol Res. 45, 123-43.
• 1. Richards KA
  2. Chaves FA
  3. Sant AJ
  (2009 Jul 01). Infection of HLA-DR1 transgenic mice with a human isolate of influenza a virus (H1N1) primes a diverse CD4 T-cell repertoire that includes CD4 T cells with heterosubtypic cross-reactivity to avian (H5N1) influenza virus. J Virol. 83, 6566-77.
• 1. Weaver JM
  2. Chaves FA
  3. Sant AJ
  (2009 May 26). Abortive activation of CD4 T cell responses during competitive priming in vivo. Proc Natl Acad Sci U S A. 106, 8647-52.
• 1. Weaver JM
  2. Lazarski CA
  3. Richards KA
  4. Chaves FA
  5. Jenks SA
  6. Menges PR
  7. Sant AJ
  (2008 Sep 01). Immunodominance of CD4 T cells to foreign antigens is peptide intrinsic and independent of molecular context: implications for vaccine design. J Immunol. 181, 3039-48.
• 1. Bandyopadhyay A
  2. Arneson L
  3. Beeson C
  4. Sant AJ
  (2008 Mar 01). The relative energetic contributions of dominant P1 pocket versus hydrogen bonding interactions to peptide:class II stability: implications for the mechanism of DM function. Mol Immunol. 45, 1248-57.
• 1. Menges PR
  2. Jenks SA
  3. Bikoff EK
  4. Friedmann DR
  5. Knowlden ZA
  6. Sant AJ
  (2008 Feb 01). An MHC class II restriction bias in CD4 T cell responses toward I-A is altered to I-E in DM-deficient mice. J Immunol. 180, 1619-33.
• 1. Richards KA
  2. Chaves FA
  3. Krafcik FR
  4. Topham DJ
  5. Lazarski CA
  6. Sant AJ
  (2007 Jul 01). Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin. J Virol. 81, 7608-19.
• 1. Sant AJ
  2. Chaves FA
  3. Krafcik FR
  4. Lazarski CA
  5. Menges P
  6. Richards K
  7. Weaver JM
  (2007 Jun 01). Immunodominance in CD4 T-cell responses: implications for immune responses to influenza virus and for vaccine design. Expert Rev Vaccines. 6, 357-68.
• 1. Chaves FA
  2. Sant AJ
  (2007 May 01). Measurement of peptide dissociation from MHC class II molecules. Curr Protoc Immunol. Chapter 18, Unit 18.14.
• 1. Chaves FA
  2. Richards KA
  3. Torelli A
  4. Wedekind J
  5. Sant AJ
  (2006 May 23). Peptide-binding motifs for the I-Ad MHC class II molecule: alternate pH-dependent binding behavior. Biochemistry. 45, 6426-33.
• 1. Lazarski CA
  2. Chaves FA
  3. Sant AJ
  (2006 May 15). The impact of DM on MHC class II-restricted antigen presentation can be altered by manipulation of MHC-peptide kinetic stability. J Exp Med. 203, 1319-28.
• 1. Sant AJ
  2. Chaves FA
  3. Jenks SA
  4. Richards KA
  5. Menges P
  6. Weaver JM
  7. Lazarski CA
  (2005 Oct 01). The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes. Immunol Rev. 207, 261-78.
• 1. Lazarski CA
  2. Chaves FA
  3. Jenks SA
  4. Wu S
  5. Richards KA
  6. Weaver JM
  7. Sant AJ
  (2005 Jul 01). The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity. 23, 29-40.
• 1. Chaves FA
  2. Hou P
  3. Wu S
  4. Sant AJ
  (2005 May 01). Replacement of the membrane proximal region of I-A(d) MHC class II molecule with I-E-derived sequences promotes production of an active and stable soluble heterodimer without altering peptide-binding specificity. J Immunol Methods. 300, 74-92.
• 1. Arneson LS
  2. Katz JF
  3. Liu M
  4. Sant AJ
  (2001 Dec 15). Hydrogen bond integrity between MHC class II molecules and bound peptide determines the intracellular fate of MHC class II molecules. J Immunol. 167, 6939-46.
• 1. McFarland BJ
  2. Katz JF
  3. Beeson C
  4. Sant AJ
  (2001 Jul 31). Energetic asymmetry among hydrogen bonds in MHC class II*peptide complexes. Proc Natl Acad Sci U S A. 98, 9231-6.
• 1. Nanda NK
  2. Sant AJ
  (2000 Sep 18). DM determines the cryptic and immunodominant fate of T cell epitopes. J Exp Med. 192, 781-8.
• 1. Arneson LS
  2. Peterson M
  3. Sant AJ
  (2000 Aug 15). The MHC class II molecule I-Ag7 exists in alternate conformations that are peptide dependent. J Immunol. 165, 2059-67.
• 1. Sant AJ
  2. Beeson C
  3. McFarland B
  4. Cao J
  5. Ceman S
  6. Bryant PW
  7. Wu S
  (1999 Dec 01). Individual hydrogen bonds play a critical role in MHC class II: peptide interactions: implications for the dynamic aspects of class II trafficking and DM-mediated peptide exchange. Immunol Rev. 172, 239-53.
• 1. McFarland BJ
  2. Beeson C
  3. Sant AJ
  (1999 Oct 01). Cutting edge: a single, essential hydrogen bond controls the stability of peptide-MHC class II complexes. J Immunol. 163, 3567-71.
• 1. Bryant PW
  2. Roos P
  3. Ploegh HL
  4. Sant AJ
  (1999 Sep 01). Deviant trafficking of I-Ad mutant molecules is reflected in their peptide binding properties. Eur J Immunol. 29, 2729-39.
• 1. Ceman S
  2. Wu S
  3. Jardetzky TS
  4. Sant AJ
  (1998 Dec 07). Alteration of a single hydrogen bond between class II molecules and peptide results in rapid degradation of class II molecules after invariant chain removal. J Exp Med. 188, 2139-49.
• 1. Peterson M
  2. Sant AJ
  (1998 Sep 15). The inability of the nonobese diabetic class II molecule to form stable peptide complexes does not reflect a failure to interact productively with DM. J Immunol. 161, 2961-7.
• 1. Tan LJ
  2. Ceman S
  3. Chervonsky A
  4. Rodriguez-Paris J
  5. Steck TL
  6. Sant AJ
  (1997 Jun 01). Late events in the intracellular sorting of major histocompatibility complex class II molecules are regulated by the 80-82 segment of the class II beta chain. Eur J Immunol. 27, 1479-88.
• 1. Stebbins CC
  2. Peterson ME
  3. Suh WM
  4. Sant AJ
  (1996 Dec 01). DM-mediated release of a naturally occurring invariant chain degradation intermediate from MHC class II molecules. J Immunol. 157, 4892-8.
• 1. Katz JF
  2. Stebbins C
  3. Appella E
  4. Sant AJ
  (1996 Nov 01). Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. J Exp Med. 184, 1747-53.
• 1. Ceman S
  2. Sant AJ
  (1995 Dec 01). The function of invariant chain in class II-restricted antigen presentation. Semin Immunol. 7, 373-87.
• 1. Chervonsky A
  2. Sant AJ
  (1995 Apr 01). In the absence of major histocompatibility complex class II molecules, invariant chain is translocated to late endocytic compartments by autophagy. Eur J Immunol. 25, 911-8.
• 1. Stebbins CC
  2. Loss GE
  3. Elias CG
  4. Chervonsky A
  5. Sant AJ
  (1995 Jan 01). The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent. J Exp Med. 181, 223-34.
• 1. Chervonsky AV
  2. Gordon L
  3. Sant AJ
  (1994 Jul 01). A segment of the MHC class II beta chain plays a critical role in targeting class II molecules to the endocytic pathway. Int Immunol. 6, 973-82.
• 1. Katz JF
  2. Sant AJ
  (1994 Feb 15). T cell receptor recognition of MHC class II alloantigens is highly cell type dependent. J Immunol. 152, 1629-40.
• 1. Sant AJ
  2. Miller J
  (1994 Feb 01). MHC class II antigen processing: biology of invariant chain. Curr Opin Immunol. 6, 57-63.
• 1. Sant AJ
  (1994 Jan 01). Endogenous antigen presentation by MHC class II molecules. Immunol Res. 13, 253-67.
• 1. Loss GE
  2. Elias CG
  3. Fields PE
  4. Ribaudo RK
  5. McKisic M
  6. Sant AJ
  (1993 Jul 01). Major histocompatibility complex class II-restricted presentation of an internally synthesized antigen displays cell-type variability and segregates from the exogenous class II and endogenous class I presentation pathways. J Exp Med. 178, 73-85.
• 1. Sant AJ
  (1993 Jun 15). Isotypic residues in the membrane proximal domain of MHC class II beta-chains control activation of CD4+ T cells. J Immunol. 150, 5299-310.
• 1. Loss GE
  2. Sant AJ
  (1993 Apr 15). Invariant chain retains MHC class II molecules in the endocytic pathway. J Immunol. 150, 3187-97.
• 1. Sant AJ
  2. Hendrix LR
  3. Coligan JE
  4. Maloy WL
  5. Germain RN
  (1991 Oct 01). Defective intracellular transport as a common mechanism limiting expression of inappropriately paired class II major histocompatibility complex alpha/beta chains. J Exp Med. 174, 799-808.
• 1. Sant AJ
  2. Dainty JC
  3. Kim MJ
  (1989 Nov 01). Comparison of surface scattering between identical, randomly rough metal and dielectric diffusers. Opt Lett. 14, 1183-5.